BPC-157 Can Now Be Compounded: What It Means for Patients
The FDA’s new interim enforcement discretion policy, published October 28 2026, allows licensed 503A pharmacies to compound BPC-157 for individual patients with a prescription. Here is what the change means, what it does not change, and how to decide whether a compounded prescription is right for you.
Yes, BPC-157 can now be legally compounded by state-licensed 503A pharmacies when a U.S.-licensed prescriber writes a patient-specific prescription. The October 28 2026 FDA interim enforcement policy does not approve BPC-157 as a drug, and it does not add the peptide to the official 503A bulks list. Instead, the policy says the FDA “does not intend to take enforcement action” when pharmacies meet strict quality, labeling and safety-reporting conditions. Research in humans remains limited and short-term, so patients and prescribers must weigh the unknowns carefully.
- The October 2026 interim policy covers six peptides, including BPC-157, but is not full FDA approval.
- Only state-licensed 503A pharmacies may compound BPC-157, and only for a named patient after a prescriber signs an individual prescription.
- BPC-157 has shown tissue-healing effects in animal studies and small human trials, but definitive safety and efficacy data are lacking (Sikiric et al., 2018) (Sikiric et al., 2020).
- Research-use-only (RUO) vials sold online remain outside the policy and are still unregulated for human use.
- Rx.com plans to offer prescription compounded versions of BPC-157 through U.S.-licensed providers and a 503A pharmacy (coming soon).
BPC-157 is a gastric peptide still considered experimental
BPC-157 is a 15-amino-acid fragment isolated from human gastric juices. In laboratory and small clinical studies it appears to speed healing of a wide range of tissues, from ulcers to tendon injuries (Sikiric et al., 2018) (Sikiric et al., 2020). The acronym stands for “Body-Protecting Compound.” Because the peptide is found naturally in the stomach, early investigators proposed it might act as a broad cytoprotective agent, and animal work supports that idea (Sikiric et al., 2016) (Bilic et al., 2005).
BPC-157 is not an FDA-approved drug. No brand-name or generic product has been evaluated through the normal Investigational New Drug (IND) and New Drug Application (NDA) process. The interim policy does not change that status-it only signals that for now the agency will exercise enforcement discretion if certain compounding conditions are met.
For a deeper dive into the molecule, see our mechanism explainer and the ongoing human studies tracker.
How the 2026 compounding policy works-answering the key questions
The October 28 2026 policy is an “interim access” pathway: it lets 503A pharmacies compound BPC-157 if they follow strict ingredient-quality, manufacturing, labeling and adverse-event-reporting rules. The FDA explicitly states that the peptide is not added to the 503A bulks list and remains an unapproved drug.
Unlike an FDA approval, enforcement discretion can be withdrawn at any time if safety or quality problems emerge. The agency also notes that the policy does not bind state pharmacy boards, which may set their own rules.
| Regulatory pathway | What it allows | What it does not allow |
|---|---|---|
| New Drug Application | Nationwide commercial sale after FDA-verified trials | Skipping quality and safety studies |
| 503A Compounding (normal) | Patient-specific compounding with ingredients on FDA’s bulks list | Using ingredients not on the bulks list |
| Interim peptide policy (BPC-157) | Patient-specific compounding despite not being on the bulks list | FDA approval, or use of research-use-only products |
Only 503A pharmacies with a patient prescription can compound BPC-157
Under the policy, compounding is limited to state-licensed 503A pharmacies and physicians, and each preparation must be for a specific patient with a prescription.
The policy sets conditions in four areas: ingredient quality, manufacturing standards, labeling and safety (adverse event) reporting.
For context on how BPC-157’s absence from the bulks list normally blocks compounding, see our explainer on the 503A bulks list.
Human evidence is promising but still very limited
Most of what we know about BPC-157 comes from rodent and cell studies. Only a handful of small, short human studies exist, and none was designed to detect long-term safety problems.
FDA's staff reviewers found the BPC-157 human studies too small and too short to draw firm conclusions on safety or effectiveness.
Commonly cited lab findings-such as improved endothelial repair or protection against arrhythmias (Sikiric et al., 2026) (Barisic et al., 2013)-have not yet been replicated in large human cohorts.
States can still restrict or ban compounded BPC-157
The interim policy is federal, but state pharmacy boards set their own compounding rules, and states are not bound by it. Some boards may not follow it, so a pharmacy in your state may still decline to make BPC-157.
Always check your state’s board of pharmacy website or ask a knowledgeable provider before assuming access.
Research-use-only products remain outside the policy-and risky
Vials labeled “for research only” or “not for human use” are not covered by the policy because they are not dispensed pursuant to a prescription and typically come from unregistered labs. The interim policy applies only to prescription compounding for identified patients, with traceable ingredient lots and mandatory safety reporting.
Because these vials are sold outside the regulated supply chain, buyers have no assurance of purity, sterility, potency or accurate labeling.
If you see BPC-157 advertised online without requiring a prescription, it is almost certainly a research-use-only product.
Is a compounded BPC-157 prescription right for you?
Could you benefit from prescription BPC-157?
Check the column that best describes you:
✅ Might be reasonable to explore
- You have a hard-to-heal tendon or ligament injury and have completed standard therapy
- Your physician is knowledgeable about peptides and will monitor your progress
- You understand BPC-157 is experimental and accept the unknowns
- Access to a licensed 503A pharmacy meeting the new quality rules
🏥 Better to avoid or postpone
- You are pregnant, breastfeeding, or trying to conceive (safety data absent)
- You have active cancer or a history of cancer (no human data on tumor effects)
- You cannot commit to regular follow-up labs and provider visits
- Your only option is an RUO vial or an unverified overseas supplier
Remember, BPC-157 remains experimental. Discuss potential benefits and risks with a licensed healthcare professional who can provide balanced guidance.
Rx.com plans to offer prescription compounded versions of BPC-157 through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
🚨 When to Contact Your Healthcare Provider
Seek medical advice right away if you experience any of the following while using or considering BPC-157:
- Severe or worsening pain: could signal tendon rupture rather than healing
- Signs of infection at an injection site: redness, swelling, warmth, pus or fever
- Unexplained swelling of the legs: rare clotting disorders have not been ruled out
- Chest pain or irregular heartbeat: arrhythmia risk in humans is unknown
- Dark urine or yellowing of the skin or eyes: possible liver problems
- New or growing lumps: report any possible tumor growth promptly
- Mood changes or severe anxiety: neurochemical effects are still being studied (Sikiric et al., 2016)
- Any adverse reaction that concerns you; it is better to err on the side of caution
Scientific References
- Sikiric P, Rucman R, Turkovic B, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018.
- Sikiric P, Drmic D, Sever M, et al. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016.
- Bilic M, Bumber Z, Blagaic AB, et al. The stable gastric pentadecapeptide BPC 157, given locally, improves CO2 laser healing in mice. Burns. 2005.
- Sikiric P, Barisic I, Udovicic M, et al. Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias. Pharmaceuticals (Basel). 2026.
- Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157. Regul Pept. 2013.
- Sikiric P, Seiwerth S, Grabarevic Z, et al. Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin. Life Sci. 1993.
- fda.gov/advisory-committees/advisory-committee-calendar/j…
Frequently Asked Questions
Is BPC-157 now FDA-approved?
No. The peptide is still an unapproved drug. The October 2026 policy only states that FDA does not plan to enforce against 503A pharmacies that meet specific conditions.
Can any pharmacy compound BPC-157?
No. Only state-licensed 503A compounding pharmacies (or physician compounders) that comply with the interim policy’s quality, labeling and safety-reporting rules may do so, and each prescription must be patient-specific.
How is a prescription different from RUO vials online?
A prescription peptide is compounded by a state-licensed 503A pharmacy for you by name, under the policy's conditions on ingredient quality, manufacturing, labeling and safety reporting. RUO products have none of those safeguards and are not meant for human use.
What dose will my doctor prescribe?
Dosing has not been standardized in clinical studies. Your prescribing clinician will select a regimen and adjust it based on your response. Never self-adjust without guidance.
